SG11202111027WA - Heavy chain antibodies binding to psma - Google Patents

Heavy chain antibodies binding to psma

Info

Publication number
SG11202111027WA
SG11202111027WA SG11202111027WA SG11202111027WA SG11202111027WA SG 11202111027W A SG11202111027W A SG 11202111027WA SG 11202111027W A SG11202111027W A SG 11202111027WA SG 11202111027W A SG11202111027W A SG 11202111027WA SG 11202111027W A SG11202111027W A SG 11202111027WA
Authority
SG
Singapore
Prior art keywords
psma
heavy chain
chain antibodies
antibodies binding
binding
Prior art date
Application number
SG11202111027WA
Inventor
Schooten Wim Van
Starlynn Clarke
Kevin Dang
Ben Buelow
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of SG11202111027WA publication Critical patent/SG11202111027WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202111027WA 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma SG11202111027WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830130P 2019-04-05 2019-04-05
PCT/US2020/026686 WO2020206330A1 (en) 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma

Publications (1)

Publication Number Publication Date
SG11202111027WA true SG11202111027WA (en) 2021-11-29

Family

ID=70476405

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111027WA SG11202111027WA (en) 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma

Country Status (17)

Country Link
US (2) US20220195068A1 (en)
EP (1) EP3947470A1 (en)
JP (1) JP2022526595A (en)
KR (1) KR20210149076A (en)
CN (1) CN113710707A (en)
AU (1) AU2020252556A1 (en)
CA (1) CA3133654A1 (en)
CL (1) CL2021002586A1 (en)
CO (1) CO2021013279A2 (en)
CR (1) CR20210500A (en)
EA (1) EA202192736A1 (en)
IL (1) IL286398A (en)
JO (1) JOP20210253A1 (en)
MX (1) MX2021012205A (en)
PE (1) PE20220142A1 (en)
SG (1) SG11202111027WA (en)
WO (1) WO2020206330A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641049B (en) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 CD3 binding antibodies
AU2017327723B2 (en) 2016-09-14 2022-11-17 Teneobio, Inc. CD3 binding antibodies
JP7240335B2 (en) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド Anti-BCMA heavy chain only antibody
CR20200322A (en) 2017-12-22 2021-01-12 Teneobio Inc Heavy chain antibodies binding to cd22
JOP20210323A1 (en) 2019-06-14 2023-01-30 Teneobio Inc Multispecific heavy chain antibodies binding to cd22 and cd3
EP4186564A1 (en) 2020-04-29 2023-05-31 Teneoone, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4284838A2 (en) * 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
EP4298130A2 (en) * 2021-02-25 2024-01-03 Teneobio, Inc. Anti-psma antibodies and car-t structures
CN117337303A (en) * 2021-04-16 2024-01-02 特尼奥生物股份有限公司 anti-CD 20 antibodies and CAR-T structures
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc Methods and compositions for increasing antibody production
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1864998B2 (en) 2004-07-22 2022-06-22 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
WO2010104949A2 (en) 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
ES2889906T3 (en) * 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Trispecific binding proteins and medical uses
US11236174B2 (en) * 2016-01-12 2022-02-01 Crescendo Biologics Limited Therapeutic molecules
CN105968203A (en) * 2016-02-03 2016-09-28 南昌大学 Single-domain heavy chain antibody for anti-prostate specific membrane antigen extracellular region
CN105968204B (en) * 2016-02-03 2020-01-21 中国人民解放军第三军医大学第一附属医院 Single-domain heavy chain antibody for resisting prostate specific membrane antigen
CN109641049B (en) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 CD3 binding antibodies
AU2017327723B2 (en) 2016-09-14 2022-11-17 Teneobio, Inc. CD3 binding antibodies
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA

Also Published As

Publication number Publication date
AU2020252556A1 (en) 2021-10-21
CO2021013279A2 (en) 2022-01-17
JP2022526595A (en) 2022-05-25
IL286398A (en) 2021-10-31
CL2021002586A1 (en) 2022-05-06
US20230242668A1 (en) 2023-08-03
US20220195068A1 (en) 2022-06-23
CN113710707A (en) 2021-11-26
WO2020206330A1 (en) 2020-10-08
JOP20210253A1 (en) 2023-01-30
PE20220142A1 (en) 2022-01-27
EP3947470A1 (en) 2022-02-09
MX2021012205A (en) 2022-02-21
CR20210500A (en) 2021-11-05
KR20210149076A (en) 2021-12-08
CA3133654A1 (en) 2020-10-08
EA202192736A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
IL286398A (en) Heavy chain antibodies binding to psma
IL276537A (en) Antibodies binding to gprc5d
IL283939A (en) Antibodies binding to cd3
IL279010A (en) Heavy chain antibodies binding to cd19
IL263083A (en) Single chain variable fragment cd3 binding proteins
ZA202203250B (en) Cd3 binding antibodies
IL287613A (en) Antibodies binding to gprc5d
IL263840A (en) Cd3 binding antibodies
ZA201808209B (en) Antibody for binding to interleukin 4 receptor
ZA201906358B (en) Improved antigen binding receptors
IL282590A (en) Heavy chain antibodies binding to cd38
IL279894A (en) Antibodies binding to ilt4
IL275498A (en) Heavy chain antibodies binding to cd22
SG11202108141VA (en) Novel cd40-binding antibodies
IL273235A (en) Heavy chain antibodies binding to ectoenzymes
IL292779A (en) Antibodies binding to hla-a2/mage-a4
IL269394A (en) Antibodies binding to steap-1
GB201905150D0 (en) Ant-ige antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
EP4081547A4 (en) Novel anti-fgfr2b antibodies
SG11202106990PA (en) BISPECIFIC ANTIBODY BINDING TO TfR
GB201709379D0 (en) Humanised ADAMTS13 binding antibodies
EP4081546A4 (en) Novel anti-fgfr2b antibodies
EP4081539A4 (en) Novel anti-fgfr2b antibodies